Telix at ANZSNM 2026

Telix is in Canberra this week for the ANZSNM Annual Scientific Meeting 2026. We’re proud to support the premier event for nuclear medicine in Australia and New Zealand, with Telix’s diagnostic and therapeutic programs featured across six oral presentations spanning prostate, kidney, and brain cancer.

Come meet the team at booth #29 to learn more about Telix’s extensive late-stage theranostic pipeline, along with our associated medical technologies, AI tools, and opportunities for collaboration.

Telix is also pleased to again support the ANZSNM Nurses’ Workshop, bringing together nuclear medicine nurses and allied health professionals from across Australia and New Zealand to share clinical experience and advance best practice in theranostic care.

Learn more about the presentations below

Canberra, ACT, Australia

May 15-17 2026

Abstract presentations 

May 16
May 17
May 16
Christian Testa


Austin Health
Clinical utility of CAIX-targeted and PSMA PET/CT imaging in restaging of clear cell renal cell carcinoma

Theranostics/Radiopharmaceutical Therapy

Swan Room / Torrens Room

May 16 | 2:15 PM AEST

Amitesh Sharma


Telix Pharmaceuticals
Evaluating efficacy and safety of [68Ga]-PSMA-11 PET/CT for detecting biochemical recurrence of prostate cancer in Japanese men (JRCT2031250473)

Theranostics / Radiopharmaceutical Therapy
Swan Room / Torrens Room

May 16 | 3:00 PM AEST

May 17
Prof. Andrew Scott AM


Austin Health
Phase 3 study to assess safety and efficacy of TLX250-Tx ([177Lu]-girentuximab) in advanced relapsed or recurrent ccRCC (LUTEON) NCT07197580

Clinical Trials in Theranostics, Murray Room

May 17 | 9:00 AM AEST

Prof. Andrew Scott AM


Austin Health
IPAX BrIGHT: Pivotal study of TLX101-Tx ([131I]-iodofalan) with or without lomustine vs lomustine alone for the treatment of patients with radiographically confirmed recurrent glioblastoma at first recurrence

Clinical Trials in Theranostics, Murray Room

May 17 | 9:45 AM AEST

David Han


Telix Pharmaceuticals
AI-assisted segmentation and TNM classification of PSMA PET/CT lesions for prostate cancer staging

General PET/CT, Murray Room

May 17 | 2:15 PM AEST

Andrew Nguyen


St Vincent’s Hospital Sydney
Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BiPASS) NCT07052214

General PET/CT, Murray Room

May 17 | 2:45 PM AEST